Last updated: July 12, 2026
OPHTHOCORT is a branded ophthalmic corticosteroid combination product. The investment case hinges on: (1) whether OPHTHOCORT has a coded NDA with Orange Book listings for patent-protected components and formulation/manufacturing IP, (2) whether any Paragraph IV challenges or branded-to-generic settlements exist, and (3) how FDA exclusivity and remaining patent life line up versus clinical demand in ophthalmology.
No patent, FDA regulatory, litigation, or Orange Book dataset identifiers were provided for “OPHTHOCORT.” Under the operating constraints, a complete and accurate patent-regulatory fundamentals analysis cannot be produced without risking factual errors.
What patents protect OPHTHOCORT ophthalmic corticosteroid combination products?
Answer: Not determinable from the provided information.
Which active ingredients are in OPHTHOCORT?
Answer: Not determinable from the provided information.
How many formulation and manufacturing patents cover OPHTHOCORT?
Answer: Not determinable from the provided information.
Which assignees hold OPHTHOCORT patents in the US?
Answer: Not determinable from the provided information.
What is the Orange Book status of OPHTHOCORT (NDA, listed patents, expiry, exclusivity)?
Answer: Not determinable from the provided information.
Is OPHTHOCORT listed under an NDA or ANDA in FDA databases?
Answer: Not determinable from the provided information.
What is OPHTHOCORT’s patent term expiration and regulatory exclusivity end date?
Answer: Not determinable from the provided information.
Which listed patents drive the “last-to-expire” barrier for generics?
Answer: Not determinable from the provided information.
When does OPHTHOCORT lose exclusivity for generics and how do exclusivity and patents interact?
Answer: Not determinable from the provided information.
What is the exclusivity type (3-year, 5-year, 7-year, pediatric, or orphan) tied to the product?
Answer: Not determinable from the provided information.
When do key patents expire versus any FDA exclusivity?
Answer: Not determinable from the provided information.
What patent litigation affects OPHTHOCORT (Paragraph IV, settlements, court outcomes)?
Answer: Not determinable from the provided information.
Are there any Paragraph IV challenges for OPHTHOCORT?
Answer: Not determinable from the provided information.
Did OPHTHOCORT face Hatch-Waxman settlements that cap generic launch?
Answer: Not determinable from the provided information.
What is the litigation timeline (filings, injunctions, dismissals, trial dates)?
Answer: Not determinable from the provided information.
What formulations are protected by OPHTHOCORT patents (vehicle, preservatives, suspension vs solution)?
Answer: Not determinable from the provided information.
Are there patents on ophthalmic suspension particle size or viscosity?
Answer: Not determinable from the provided information.
Are there patents on preservatives, buffer systems, and pH ranges?
Answer: Not determinable from the provided information.
Are there patents on sterile manufacturing or container-closure systems?
Answer: Not determinable from the provided information.
What generic entry risks exist for OPHTHOCORT (bioequivalence, formulation change, or process/IP barriers)?
Answer: Not determinable from the provided information.
What barriers prevent “at-risk” ANDA launches for OPHTHOCORT?
Answer: Not determinable from the provided information.
How much would a generic need to change to design around OPHTHOCORT patents?
Answer: Not determinable from the provided information.
How does OPHTHOCORT compare with competing ophthalmic corticosteroids on IP and launch timing?
Answer: Not determinable from the provided information.
Which brands and generics are the closest substitutes by mechanism of action and indication?
Answer: Not determinable from the provided information.
Do competitors have near-term patent cliffs in the same therapeutic segment?
Answer: Not determinable from the provided information.
What FDA regulatory pathway and product status drive the OPHTHOCORT investment thesis?
Answer: Not determinable from the provided information.
Is OPHTHOCORT approved for multiple indications under one label?
Answer: Not determinable from the provided information.
What is OPHTHOCORT’s current manufacturing and distribution status?
Answer: Not determinable from the provided information.
Is the product supply constrained or stable based on FDA signals?
Answer: Not determinable from the provided information.
Commercial exposure: what revenue and volume signals matter for OPHTHOCORT?
Answer: Not determinable from the provided information.
How concentrated is OPHTHOCORT demand in ophthalmology subsegments?
Answer: Not determinable from the provided information.
What share is at risk from authorized generics, OTC shifts, or channel substitutions?
Answer: Not determinable from the provided information.
Key Takeaways
- A complete investment and fundamentals analysis for OPHTHOCORT requires FDA identifier-level inputs (NDA/label, Orange Book patent list, expiration dates) and litigation identifiers. Those were not provided, so a data-accurate assessment cannot be produced under the constraints.
FAQs
-
What is the Orange Book “last patent to expire” for OPHTHOCORT?
Not determinable from the provided information.
-
Are there any active Paragraph IV challenges against OPHTHOCORT?
Not determinable from the provided information.
-
What is the earliest generic launch date for OPHTHOCORT under Hatch-Waxman timelines?
Not determinable from the provided information.
-
Do OPHTHOCORT patents cover formulation variables like pH, preservatives, or viscosity?
Not determinable from the provided information.
-
How do patent cliffs in competing ophthalmic corticosteroids affect OPHTHOCORT pricing power?
Not determinable from the provided information.
References
No sources were cited because no OPHTHOCORT-specific FDA, Orange Book, patent, or litigation records were provided.
